Tocilizumab (ROACTEMRA©) was considered since compelling data suggested that IL-6 could be a key cytokine in COVID-19 pathophysiology, and that drugs targeting IL-6 such as tocilizumab are an appealing therapeutic strategy [55,56]. The gene discussed is IL6; the disease is COVID-19.